22 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02145 | C1 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 ±2 µMol/L |
| dbacp02146 | C1 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 22 ±5 µMol/L |
| dbacp02148 | C2 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.9 ± 0.3 µMol/L |
| dbacp02149 | C2 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 1.71 ± 0.6 µMol/L |
| dbacp02150 | C3 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 15 ± 2 µMol/L |
| dbacp02151 | C3 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 92 ± 2 µMol/L |
| dbacp02152 | C4 | KWβ2,2KK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 12.6 ± 0.6 µMol/L |
| dbacp02153 | C4 | KWβ2,2KK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 99 ± 15 µMol/L |
| dbacp02154 | C5 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11 ± 2 µMol/L |
| dbacp02155 | C5 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 23 ± 3 µMol/L |
| dbacp02156 | C6 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 8 ± 1 µMol/L |
| dbacp02157 | C6 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 26 ± 2 µMol/L |
| dbacp02158 | C7 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 16 ± 5 µMol/L |
| dbacp02159 | C7 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 157 ± 30 µMol/L |
| dbacp02223 | C8 | KWβ2,2KK | Not found | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 20 ± 2 µMol/L |
| dbacp02224 | C8 | KWβ2,2KK | Not found | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 226 ± 21 µMol/L |
| dbacp02225 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Calu-6 | Lung cancer | Activity : ~90% survival rate at 10 µM |
| dbacp02226 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Calu-6 | Lung cancer | Activity : <20% survival rate at 100 µM |
| dbacp02227 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Jurkat | Blood cancer | Activity : 100% survival rate at 10 µM |
| dbacp02228 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | Jurkat | Blood cancer | Activity : 0% survival rate at 100 µM |
| dbacp02229 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | SNU-601 | Gastric cancer | Activity : ~80% survival rate at 10 µM |
| dbacp02230 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-Melittin hybrid | Membrane disruptive mode of action | MTT/MTS assay | SNU-601 | Gastric cancer | Activity : 10% survival rate at 100 µM |